Zydus Lifesciences Share Price, Fundamentals and Financials
Track Zydus Lifesciences live share price, 52 week range, chart views, fundamentals, financial highlights, peers and corporate actions.
₹1,121.20
₹-0.10 · -0.01%
Zydus Lifesciences price chart
Switch between 1 Day, 5 Day, 1 Month and 1 Year views.
ZYDUSLIFE.NS one day trend
Chart data is temporarily unavailable.
Quick Fundamentals
About Zydus Lifesciences Ltd
Zydus Lifesciences is an innovation-led global life-sciences company headquartered in Ahmedabad. It develops, manufactures and markets medicines and healthcare products across India, the United States and other international markets.
Its capabilities span branded formulations, generics, complex products, APIs, vaccines, biologics, specialty therapies, consumer wellness and research-driven new chemical entities.
Business segments and investor focus
Major areas include India formulations and consumer wellness, US formulations, international formulations, APIs, alliances and research. Investors also track the innovation pipeline, inspections, product concentration and geographic mix.
Business Model
Zydus earns revenue from prescription medicines, generics, specialty therapies, APIs, vaccines, biologics and wellness products. Revenue depends on volumes, pricing, geographic mix, approvals and partnerships.
Key risks include regulatory observations, product-quality issues, delayed approvals, patent litigation, research failure, pricing pressure, raw-material inflation and currency volatility.
Profit and Loss / Financial Highlights
| Particulars | Mar 2024 | Mar 2025 | Investor Note |
|---|---|---|---|
| Revenue from Operations | ₹19,547 Cr | ₹23,242 Cr | FY25 growth about 19% |
| EBITDA | ₹5,384 Cr | ₹7,059 Cr | FY25 margin about 30.4% |
| Profit Before Tax | ₹4,823 Cr | ₹6,246 Cr | Verify audited filing |
| Adjusted Net Profit | ₹3,874 Cr | ₹4,745 Cr | FY25 growth about 23% |
| Reported Net Profit | ₹3,860 Cr | ₹4,526 Cr | Verify audited filing |
| R&D Investment | Verify annual report | ₹1,856 Cr | About 8.0% of FY25 revenue |
Verify the latest audited and quarterly figures from company and exchange filings.
Balance Sheet Highlights
| Particulars | Mar 2024 | Mar 2025 | Investor Note |
|---|---|---|---|
| Net Cash | Positive net cash | ₹4,884 Cr | Company-reported FY25 position |
| Net Debt to Equity | Verify annual report | -0.20x | Negative ratio indicates net cash |
| Net Debt to EBITDA | Verify annual report | -0.69x | Verify latest update |
| Property, Plant and Equipment | Verify annual report | Verify annual report | Manufacturing and research assets |
| Working Capital | Verify annual report | Verify annual report | Monitor inventory and receivables |
| Total Assets | Verify annual report | Verify annual report | Use latest audited filing |
Verify the latest audited balance sheet before use.
Cash Flow / Business Highlights
| Particulars | FY 2024 | FY 2025 | Investor Note |
|---|---|---|---|
| Operating Cash Flow | Verify annual report | Verify annual report | Compare with profit |
| Organic Capital Expenditure | Verify annual report | ₹1,214 Cr | Manufacturing, R&D and capacity |
| Free Cash Flow | Verify annual report | Verify annual report | Operating cash flow less capex |
| Net Cash Position | Positive | ₹4,884 Cr | Capital-allocation flexibility |
| R&D Investment | Verify annual report | ₹1,856 Cr | About 8.0% of FY25 revenue |
Key Ratios
| Metric | Mar 2024 | Mar 2025 | Investor Note |
|---|---|---|---|
| EBITDA Margin | 27.5% | 30.4% | Verify latest filing |
| Adjusted Net Profit Growth | Verify base year | 22.5% | FY25 year-on-year |
| R&D as % of Revenue | Verify annual report | 8.0% | Research intensity |
| Net Debt to Equity | Verify annual report | -0.20x | Net cash position |
| Net Debt to EBITDA | Verify annual report | -0.69x | Net cash position |
Peer Comparison
| Company | NSE Symbol | Business Focus | Key Comparison Metric |
|---|---|---|---|
| Zydus Lifesciences Ltd | ZYDUSLIFE | India, US and global pharma | Growth, margin, approvals |
| Sun Pharmaceutical Industries Ltd | SUNPHARMA | Specialty and branded generics | Specialty growth, margin |
| Dr. Reddys Laboratories Ltd | DRREDDY | Generics and services | US growth, launches |
| Cipla Ltd | CIPLA | India, respiratory and US | India growth, US pipeline |
| Lupin Ltd | LUPIN | Generics and branded pharma | US recovery, margins |
Dividends and Bonuses / Splits
| Year | Dividend Detail | Note |
|---|---|---|
| FY 2024-25 | Board recommended dividend of 1100% on face value | Verify rupee amount, approval and record date |
| Earlier years | Dividends declared in prior periods | Verify exact history |
| Future dividends | Not guaranteed | Depends on profits, cash needs and approvals |
| Action | Detail | Note |
|---|---|---|
| Bonus Issue | No current detail stated here | Verify exchange history |
| Stock Split | No current detail stated here | Verify face-value history |
| Buyback | Corporate actions may change | Verify latest announcement |
Verify the latest dividend, bonus, split and buyback details from Zydus Lifesciences investor relations and NSE/BSE filings.
Zydus Lifesciences customer and investor FAQs
What does Zydus Lifesciences do?
Zydus Lifesciences is an innovation-led global healthcare company that discovers, develops, manufactures and markets formulations, APIs, vaccines, biologics, specialty medicines and wellness products.
How does Zydus Lifesciences make money?
It earns revenue from branded and generic medicines in India, the United States and international markets, APIs, licensing, specialty products and consumer-wellness categories.
What are the main business segments of Zydus Lifesciences?
Important areas include India formulations, US formulations, international formulations, APIs, consumer wellness, vaccines, biologics, specialty products, research programmes and alliances.
What is the NSE and BSE code for Zydus Lifesciences?
The NSE symbol is ZYDUSLIFE, the BSE scrip code is 532321, and the Yahoo Finance-compatible symbol used here is ZYDUSLIFE.NS.
Which therapy areas does Zydus Lifesciences serve?
Its portfolio covers cardiology, diabetes, gastroenterology, respiratory care, pain management, oncology, infectious diseases, vaccines and other specialty and chronic-care categories.
How important is the US market to Zydus Lifesciences?
The United States is a major market. Investors monitor approvals, launches, competition, pricing, specialty products, regulatory compliance and currency movements.
What factors can affect the Zydus Lifesciences share price?
Important factors include revenue growth, product approvals, US pricing, specialty launches, research outcomes, inspections, margins, currency movements, acquisitions and litigation.
Does Zydus Lifesciences pay dividends?
The company has paid dividends, but amounts and dates can change. Verify every dividend from company and exchange filings.
Has Zydus Lifesciences issued bonus shares or stock splits?
Corporate-action history may include dividends, buybacks, bonuses or splits. Verify the complete history from NSE, BSE and company filings.
What are the main risks in the Zydus Lifesciences business model?
Risks include regulatory observations, recalls, patent litigation, research failure, delayed approvals, pricing pressure, raw-material costs, currency volatility and acquisition integration.
Which metrics should retail investors track?
Track revenue by geography, India and US growth, EBITDA margin, profit, R&D spending, cash flow, net cash or debt, approvals, launches and return ratios.
How does Zydus compare with Sun Pharma, Dr Reddys, Cipla and Lupin?
Compare therapy mix, geographic exposure, specialty pipeline, US dependence, domestic growth, margins, R&D intensity, regulatory history, cash generation and valuation.
Is Zydus Lifesciences suitable for beginner investors?
Suitability depends on valuation, risk tolerance, horizon and diversification. This page is educational and is not a buy or sell recommendation.
Where can investors verify the latest Zydus data?
Use Zydus Lifesciences investor relations and official NSE and BSE filings for audited results, shareholding and corporate actions.